- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.03. | Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 26.02. | Entrada Therapeutics: EPS übertrifft Schätzungen um 0,04 $ - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
| 26.02. | Entrada Therapeutics GAAP EPS of -$0.94 beats by $0.30, revenue of $1.3M misses by $6.11M | 1 | Seeking Alpha | ||
| 26.02. | Entrada Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 26.02. | Earnings Summary: Entrada Therapeutics Q4 | 1 | Benzinga.com | ||
| 26.02. | Entrada Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.02. | Entrada Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.01. | Entrada Therapeutics legt Zeitplan für wichtige DMD-Studiendaten vor | 3 | Investing.com Deutsch | ||
| ENTRADA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.01. | Entrada Therapeutics, Inc.: Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases | 206 | GlobeNewswire (Europe) | -- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 - -- Expects to initiate global Phase 1/2 MAD clinical... ► Artikel lesen | |
| 08.01. | Entrada Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.12.25 | Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 06.11.25 | Entrada Therapeutics: EPS verfehlt Schätzungen um 0,07 $ - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
| 06.11.25 | Entrada Therapeutics GAAP EPS of -$1.06, revenue of $1.6M | 2 | Seeking Alpha | ||
| 06.11.25 | Entrada Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Entrada Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.09.25 | Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 237 | GlobeNewswire (Europe) | BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 54,360 restricted stock units ("RSUs") and options to... ► Artikel lesen | |
| 06.08.25 | Entrada Therapeutics, Inc.: Entrada Therapeutics Reports Second Quarter 2025 Financial Results | 253 | GlobeNewswire (Europe) | -- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple... ► Artikel lesen | |
| 02.06.25 | Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 290 | GlobeNewswire (Europe) | BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units ("RSUs") to six newly-hired... ► Artikel lesen | |
| 28.05.25 | Entrada Therapeutics, Inc.: Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne ... | 349 | GlobeNewswire (Europe) | - Company on track to begin ELEVATE-45-201 in Q3 2025 - - Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 - BOSTON... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 75,00 | -2,72 % | BioNTech SE: BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs | Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren... ► Artikel lesen | |
| EVOTEC | 4,172 | +0,53 % | Evotec: Misstrauen trotz Millionen | Eine Summe in Höhe von zehn Millionen Dollar (rund 9,2 Millionen Euro) überweist der amerikanische Pharmakonzern Bristol-Myers Squibb dem Hamburger Biotechunternehmen. Es handelt sich um eine Meilensteinzahlung... ► Artikel lesen | |
| BB BIOTECH | 46,400 | -6,36 % | EQS-News: BB BIOTECH AG: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.25 pro Aktie | EQS-News: BB BIOTECH AG
/ Schlagwort(e): Hauptversammlung/Dividende
Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.25... ► Artikel lesen | |
| MEDIGENE | 0,029 | -17,42 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 34,145 | -0,29 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| BIOGEN | 158,45 | 0,00 % | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,830 | -4,07 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma erhält Meilensteinzahlung des Partners Huadong für klinische Studie mit HDP-101 in China | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma erhält Meilensteinzahlung des Partners Huadong für klinische Studie mit HDP-101 in China
18.03.2026... ► Artikel lesen | |
| ILLUMINA | 106,20 | -1,28 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,800 | +2,00 % | AtaiBeckley added to S&P Total Market, CRSP benchmark indices | ||
| INTELLIA THERAPEUTICS | 11,050 | -1,16 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,396 | -3,18 % | Megatrend Nanotechnologie - und NurExone Biologic Inc. im Zentrum der Entwicklung | ||
| GUBRA | 49,000 | -2,20 % | Gubra A/S: AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog | Gubra's partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent significant... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 49,150 | +0,90 % | ARROWHEAD PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| GALAPAGOS NV | 27,400 | -0,58 % | Galapagos NV: Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases | Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines
New partnership structure would achieve meaningfully improved financial terms... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,046 | -6,12 % | SOL Global Investments Corp.: SOL GLOBAL Announces Delay in Filing Audited Annual Financial Statements | Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCD) (FSE: 9SB0) ("SOL Global" or the "Company") announced today that it does not anticipate... ► Artikel lesen |
Das Unternehmen ENTRADA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 11,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENTRADA THERAPEUTICS INC finden Sie auf Wallstreet Online.